LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 1 | M08 | 72 | hr | 1401 | 1852 | 3978 | 0.4655 | 0.2034 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 2 | M08 | 72 | hr | 1401 | 1511 | 4213 | 0.3586 | 0.0485 |
| SK-BR-3 | XMD16-144 | 3.33 | uM | LJP5 | 3 | M08 | 72 | hr | 1401 | 1506 | 4545 | 0.3313 | 0.0433 |
| SK-BR-3 | XMD16-144 | 10 | uM | LJP5 | 1 | M07 | 72 | hr | 1401 | 1239 | 3978 | 0.3114 | -0.0786 |
| SK-BR-3 | XMD16-144 | 10 | uM | LJP5 | 2 | M07 | 72 | hr | 1401 | 1173 | 4213 | 0.2784 | -0.1060 |
| SK-BR-3 | XMD16-144 | 10 | uM | LJP5 | 3 | M07 | 72 | hr | 1401 | 1101 | 4545 | 0.2422 | -0.1325 |
| SK-BR-3 | Erlotinib | 0.04 | uM | LJP5 | 1 | M24 | 72 | hr | 1401 | 3693 | 3978 | 0.9282 | 0.9034 |
| SK-BR-3 | Erlotinib | 0.04 | uM | LJP5 | 2 | M24 | 72 | hr | 1401 | 3726 | 4213 | 0.8844 | 0.8510 |
| SK-BR-3 | Erlotinib | 0.04 | uM | LJP5 | 3 | M24 | 72 | hr | 1401 | 3720 | 4545 | 0.8183 | 0.7772 |
| SK-BR-3 | Erlotinib | 0.12 | uM | LJP5 | 1 | M23 | 72 | hr | 1401 | 3725 | 3978 | 0.9363 | 0.9144 |
| SK-BR-3 | Erlotinib | 0.12 | uM | LJP5 | 2 | M23 | 72 | hr | 1401 | 3861 | 4213 | 0.9164 | 0.8930 |
| SK-BR-3 | Erlotinib | 0.12 | uM | LJP5 | 3 | M23 | 72 | hr | 1401 | 4138 | 4545 | 0.9103 | 0.8922 |
| SK-BR-3 | Erlotinib | 0.37 | uM | LJP5 | 1 | M22 | 72 | hr | 1401 | 3776 | 3978 | 0.9491 | 0.9318 |
| SK-BR-3 | Erlotinib | 0.37 | uM | LJP5 | 2 | M22 | 72 | hr | 1401 | 4096 | 4213 | 0.9722 | 0.9648 |
| SK-BR-3 | Erlotinib | 0.37 | uM | LJP5 | 3 | M22 | 72 | hr | 1401 | 4292 | 4545 | 0.9441 | 0.9334 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 1 | M21 | 72 | hr | 1401 | 3710 | 3978 | 0.9325 | 0.9093 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 2 | M21 | 72 | hr | 1401 | 3963 | 4213 | 0.9406 | 0.9243 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 3 | M21 | 72 | hr | 1401 | 4546 | 4545 | 1.0000 | 1.0000 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 1 | M20 | 72 | hr | 1401 | 3419 | 3978 | 0.8594 | 0.8084 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 2 | M20 | 72 | hr | 1401 | 3848 | 4213 | 0.9133 | 0.8890 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 3 | M20 | 72 | hr | 1401 | 3897 | 4545 | 0.8573 | 0.8265 |
| SK-BR-3 | Erlotinib | 10 | uM | LJP5 | 1 | M19 | 72 | hr | 1401 | 1831 | 3978 | 0.4602 | 0.1943 |
| SK-BR-3 | Erlotinib | 10 | uM | LJP5 | 2 | M19 | 72 | hr | 1401 | 2190 | 4213 | 0.5198 | 0.3246 |
| SK-BR-3 | Erlotinib | 10 | uM | LJP5 | 3 | M19 | 72 | hr | 1401 | 2159 | 4545 | 0.4749 | 0.2899 |
| SK-BR-3 | Gefitinib | 0.04 | uM | LJP6 | 1 | N12 | 72 | hr | 1401 | 3986 | 4139 | 0.9630 | 0.9524 |